Galectin-7和S100A9表达与宫颈鳞癌发生发展的相关性

目的: 探讨galectin-7和S100A9表达与宫颈鳞癌发生、发展的关系。方法: 采用免疫组织化学法检测243例宫颈上皮内瘤变 (CIN)及宫颈鳞癌标本中galectin-7和S100A9的表达情况，结合临床病理资料，分析其与宫颈鳞癌发生、发展的关系。结果: Galectin-7和S100A9在CIN及宫颈鳞癌中表达差异有统计学意义(均P<0.05)，galectin-7在正常宫颈组织、CIN I 级、CIN II 级、 CIN III 级、宫颈鳞癌中阳性表达率分别为56.7%，41.9%，32.0%，27.3%，25.0%，组间比较发现galectin-7在正常宫颈组织与宫颈鳞癌中表达差异有统计学意义(P<0.0045)。S100A9在正常宫颈组织、CIN I 级、CIN II 级、 CIN III 级、宫颈鳞癌中阳性表达率分别为 80.0%，77.4%，48.0%，27.3%，20.2%，组间比较发现S100A9在正常宫颈组织与CIN III 级、正常宫颈组织与宫颈鳞癌、CIN I 级与CIN III 级、CIN I 级与宫颈鳞癌、CIN II级与宫颈鳞癌中表达差异均有统计学意义(均P<0.0045)。Galectin-7与S100A9在CIN及宫颈鳞癌中表达呈正相关，但关系较弱 (r_s=0.298，P<0.001)。Galectin-7和S100A9表达均与宫颈鳞癌临床分期、淋巴结转移有关(均P<0.05)，而与年龄、分化程度无关(P≥0.05); galectin-7表达与宫颈鳞癌患者预后有关(P<0.05)。单因素Cox回归分析示国际妇产科联盟 (FIGO)分期、淋巴结转移及galectin-7与宫颈鳞癌患者5年生存率有关，多因素Cox分析进一步验证了这一结果。结论: Galectin-7和S100A9表达与宫颈鳞癌发生、宫颈鳞癌临床分期、淋巴结转移有关，galectin-7表达可能还与宫颈鳞癌患者预后有关。宫颈鳞癌患者长期生存时间与FIGO分期、淋巴结转移及galectin-7的表达有关。

Expression of galectin-7 and S100A9 and development of cervical squamous carcinoma

Objective: To observe the correlation between the expression of galectin-7 and S100A9 with the development of cervical squamous carcinoma.Methods: Immunohistochemical SP staining was used to detect the expression of galectin-7 and S100A9 in 243 patients with cervical intraepithelial neoplasia (CIN) or cervical squamous carcinoma. The association of clinical data with galectin-7 and S100A9 expression was examined.Results: The expression of galectin-7 and S100A9 in CIN and cervical squamous carcinoma was significantly different (P<0.05). The positive rates of galectin-7 in normal cervical tissues, CIN I, CIN II, CIN III, and cervical squamous carcinoma were 56.7%, 41.9%, 32.0%, 27.3%, and 25.0%, repectively. Statistic analysis found significant difference between the normal cervical tissues and cervical squamous carcinoma (P<0.0045). The positive rates of S100A9 in CIN I, CIN II, CIN III, and cervical squamous carcinoma were 80.0%, 77.4%, 48.0%, 27.3%, and 20.2%. Statistic analysis showed significant difference between the normal tissues and CIN III, the normal cervical tissues and cervical squamous carcinoma, CIN I and CIN III, CIN I and cervical squamous carcinoma, CIN II and cervical squamous carcinoma (P<0.0045). A positive correlation was found between galectin-7 and S100A9 expression in CIN and cervical squamous carcinoma (r_s=0.298, P<0.001). Expressions of both galectin-7 and S100A9 in cervical squamous carcinoma were associated with the clinical stage and lymph nodes (P<0.05), but not with patient's age and degree of differentiation (P>0.05). Expression of galectin-7 was associated with the survival rate of patients with cervical squamous carcinoma (P<0.05). Univariate analysis of Cox proportional hazards regression model revealed that the FIGO stage, lymph nodes metastasis, and the expression of galectin-7 were relevant to the 5 year survival rate of patients with cervical squamous carcinoma, which was comfirmed by multiple analysis of Cox proportional hazards regression model.Conclusion: Expression of galectin-7 and S100A9 is related with cervical the tumorigenesis of carcinoma, clinical stage, and lymph nodes of cervical squamous carcinoma. Galectin-7 is probably associated with the prognosis. The long-term survival of patients with cervical carcinoma may be associated with FIGO stage, lymph node metastasis, and the expression of galectin-7.